CA
NZ
UK
AU
IND
US
…
Optimi Health Corp. operates as a GMP-certified pharmaceutical drug manufacturing company in Canada. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company offers raw mushroom biomass, mushroom extracts, and mushroom supplements, as well as a range of manufacturing of drug products. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was formerly known as 1251418 BC Ltd. and changed its name to Optimi Health Corp. in August 2020. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Available disclosures indicate Optimi Health Corp is a Canada-listed company in the consumer health and wellness sector, focused on development and distribution of natural health products. Long-term drivers may include aging demographics, rising preventive-care demand and expansion into retail and e-commerce channels, which could support brand scaling and revenue diversification; investors may find exposure to consumer-health growth appealing.
Material risks include limited public disclosure, low liquidity, regulatory and product-safety requirements, strong competition in nutraceuticals and execution or financing risks that could cause dilution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -3.71M | -6.04M | -5.19M | -7.35M | -6.02M |
| Net income | -3.71M | -6.04M | -5.19M | -7.35M | -6.02M |
| Selling general administrative | 2.72M | 3.85M | 3.82M | 7.02M | 5.77M |
| Gross profit | -0.07M | 0.27M | 0.20M | 0.05M | 0.00M |
| Reconciled depreciation | 0.95M | 0.87M | 0.73M | 0.29M | 0.05M |
| Ebit | - | - | - | -6.93M | -5.35M |
| Ebitda | - | - | - | -7.03M | -5.95M |
| Operating income | -4.61M | -5.61M | -5.27M | -7.39M | -6.06M |
| Interest expense | 0.53M | 0.43M | 0.04M | 0.03M | 0.02M |
| Interest income | 0.01M | 0.00M | 0.14M | 0.07M | 0.06M |
| Net interest income | -0.52M | -0.43M | 0.09M | 0.04M | 0.04M |
| Total revenue | 0.43M | 0.39M | 0.18M | 0.08M | 0.00M |
| Total operating expenses | 5.04M | 6.00M | 5.45M | 7.47M | 6.06M |
| Cost of revenue | 0.49M | 0.12M | -0.02M | 0.03M | 0.00M |
| Total other income expense net | 1.42M | - | -0.01M | - | - |
| Net income from continuing ops | -3.71M | -6.04M | -5.19M | -7.35M | -6.02M |
| Net income applicable to common shares | - | - | - | -7.35M | -6.02M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 15.21M | 14.55M | 16.49M | 16.82M | 23.46M |
| Other current assets | - | - | - | 0.01M | 0.02M |
| Total liab | 8.64M | 4.98M | 3.28M | 0.80M | 2.40M |
| Total stockholder equity | 6.57M | 9.58M | 13.21M | 16.02M | 21.07M |
| Common stock | - | - | - | 26.61M | 25.16M |
| Capital stock | 31.69M | 31.16M | 28.70M | 26.61M | 25.16M |
| Retained earnings | -27.24M | -23.61M | -17.65M | -13.43M | -6.19M |
| Other assets | - | - | - | 0.01M | 0.26M |
| Cash | 1.15M | 0.10M | 1.34M | 1.89M | 8.43M |
| Total current liabilities | 8.48M | 3.22M | 1.61M | 0.73M | 2.24M |
| Net debt | 5.19M | 2.61M | 0.29M | - | - |
| Short long term debt | 6.33M | 0.96M | - | - | - |
| Other stockholder equity | - | - | - | 2.83M | 2.10M |
| Property plant equipment | - | - | - | 14.38M | 8.90M |
| Total current assets | 1.83M | 1.23M | 2.43M | 2.43M | 14.30M |
| Net tangible assets | - | - | - | 16.02M | 21.07M |
| Short term investments | - | - | - | 0.00M | 4.00M |
| Net receivables | 0.10M | 0.12M | 0.17M | 0.10M | 0.19M |
| Long term debt | - | 1.76M | 1.64M | - | - |
| Inventory | 0.31M | 0.89M | 0.78M | 0.26M | 0.12M |
| Accounts payable | 1.19M | 0.75M | 0.90M | 0.56M | 2.11M |
| Non current assets total | 13.39M | 13.32M | 14.06M | 14.40M | 9.16M |
| Capital lease obligations | 0.18M | 0.03M | 0.07M | 0.16M | 0.25M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | - | -0.15M | -0.71M | 4.00M | -4.00M |
| Change to liabilities | - | - | - | 0.12M | 0.26M |
| Total cashflows from investing activities | - | - | - | -3.15M | -9.19M |
| Net borrowings | 3.40M | 0.96M | 1.92M | -0.11M | -0.05M |
| Total cash from financing activities | 3.76M | 3.19M | 3.76M | 1.19M | 19.18M |
| Change to operating activities | - | - | - | 1.51M | -1.64M |
| Net income | -3.71M | -6.04M | -5.19M | -7.35M | -6.02M |
| Change in cash | 1.04M | -1.24M | -0.54M | -6.54M | 3.96M |
| Begin period cash flow | 0.10M | 1.34M | 1.89M | 8.43M | 4.47M |
| End period cash flow | 1.15M | 0.10M | 1.34M | 1.89M | 8.43M |
| Total cash from operating activities | -2.63M | -4.28M | -3.60M | -4.58M | -6.02M |
| Issuance of capital stock | 0.40M | 2.04M | 1.84M | 0.00M | 18.86M |
| Depreciation | 0.95M | 0.87M | 0.73M | 0.29M | 0.05M |
| Other cashflows from investing activities | - | - | - | - | -0.26M |
| Change to inventory | 0.50M | 0.02M | -0.21M | -0.26M | -0.26M |
| Change to account receivables | 0.03M | 0.04M | -0.07M | 0.09M | -0.10M |
| Other cashflows from financing activities | - | - | - | - | 0.05M |
| Change to netincome | - | - | - | 1.03M | 1.44M |
| Capital expenditures | 0.09M | 0.15M | 0.80M | 7.15M | 4.94M |
| Change in working capital | 1.25M | 0.76M | 0.83M | 1.45M | -1.49M |
| Stock based compensation | 0.05M | 0.06M | 0.16M | 1.01M | 1.26M |
| Other non cash items | 0.26M | 0.07M | 0.03M | 0.02M | 0.18M |
| Free cash flow | -2.72M | -4.43M | -4.41M | -11.73M | -10.96M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OPTI Optimi Health Corp |
0.14 4.47% |
3.27 | - | - | 179.96 | 6.75 | 206.22 | -5.56 |
| GTII Green Thumb Industries Inc |
0.82 9.36% |
9.58 | 14.70 | 34.84 | 1.91 | 0.86 | 1.61 | 3.95 |
| CL Cresco Labs Inc |
0.01 1.27% |
0.80 | - | 105.26 | 0.70 | 0.99 | 1.32 | 42.44 |
| JUSH Jushi Holdings Inc |
- -% |
0.63 | - | 17.86 | 0.52 | 0.69 | 1.41 | 9.56 |
| GRIN Grown Rogue International Inc |
- -% |
0.50 | 23.50 | - | 3.62 | 4.10 | 3.13 | 11.19 |
Optimi Health Corp. operates as a GMP-certified pharmaceutical drug manufacturing company in Canada. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company offers raw mushroom biomass, mushroom extracts, and mushroom supplements, as well as a range of manufacturing of drug products. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was formerly known as 1251418 BC Ltd. and changed its name to Optimi Health Corp. in August 2020. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.
1200-609 Granville Street, Princeton, BC, Canada, V0X 1W0
778-761-4551
6
| Name | Title | Year Born |
|---|---|---|
| Mr. Dane Stevens | Co-Founder, CEO, Chief Marketing Officer & Director | 1990 |
| Mr. Bryan Edward Safarik | Co-Founder, COO & Director | 1985 |
| Mr. Jacob Safarik | Co-Founder, Interim CFO & Director | 1988 |
| Dr. Preston A. Chase | Chief Science Officer | NA |
| Ms. Ann Little | Human Resources Manager | NA |
| Ms. Leah Hodges | Corporate Secretary | 1983 |
| Mr. John James Wilson | Co-Founder & Chairman | 1989 |
| Mr. Dane Stevens | Co-Founder, CEO, Chief Marketing Officer & Director | 1989 |
| Mr. Jacob Safarik | Co-Founder, CFO & Director | 1988 |
| Ms. Leah Hodges | Corporate Secretary | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...